Acquisitions - Schedule of Components of Purchase Price (Details) - USD ($) $ in Thousands							12 Months Ended
	Jan. 03, 2023	Dec. 30, 2021	Dec. 08, 2021	Sep. 30, 2021	Feb. 25, 2021	Jan. 15, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Purchase Price
Fair value of equity awards exchanged							$ 0	$ 43,000	$ 0
Fair value of contingent consideration							$ 0	183,000	$ 0
The Binding Site Group | Subsequent Event
Purchase Price
Cash paid	$ 2,420,000
Debt settled	310,000
Cash acquired	20,000
Total purchase price	2,710,000
Net Assets Acquired [Abstract]
Definite-lived intangible assets:	1,070,000
Goodwill	1,770,000
Net tangible assets	150,000
Deferred tax assets (liabilities)	(280,000)
Total net assets acquired	$ 2,710,000
PPD
Purchase Price
Cash paid			$ 17,237,000
Fair value of equity awards exchanged			43,000
Fair value of contingent consideration			0
Cash acquired			(1,244,000)
Total purchase price			16,036,000
Net Assets Acquired [Abstract]
Current assets			2,477,000
Property, plant and equipment			527,000
Goodwill			13,949,000
Other assets			1,060,000
Contract liabilities			(1,539,000)
Deferred tax assets (liabilities)			(1,782,000)
Finance lease liabilities			(90,000)
Debt assumed			(4,299,000)
Other liabilities assumed			(2,034,000)
Redeemable noncontrolling interest			(122,000)
Total net assets acquired			16,036,000
PPD | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:			6,257,000
PPD | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:			0
PPD | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:			594,000
PPD | Backlog
Net Assets Acquired [Abstract]
Definite-lived intangible assets:			$ 1,038,000
PeproTech
Purchase Price
Cash paid		$ 1,946,000
Fair value of contingent consideration		0
Cash acquired		(83,000)
Total purchase price		1,863,000
Net Assets Acquired [Abstract]
Current assets		58,000
Property, plant and equipment		18,000
Goodwill		1,198,000
Other assets		11,000
Contract liabilities		0
Deferred tax assets (liabilities)		(192,000)
Finance lease liabilities		0
Debt assumed		0
Other liabilities assumed		(22,000)
Total net assets acquired		1,863,000
PeproTech | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:		510,000
PeproTech | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:		282,000
PeproTech | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:		$ 0
European Viral Vector Business
Purchase Price
Cash paid						$ 848,000
Fair value of contingent consideration						0
Cash acquired						(18,000)
Total purchase price						830,000
Net Assets Acquired [Abstract]
Current assets						39,000
Property, plant and equipment						59,000
Goodwill						600,000
Other assets						3,000
Contract liabilities						(59,000)
Deferred tax assets (liabilities)						(80,000)
Finance lease liabilities						(24,000)
Debt assumed						0
Other liabilities assumed						(35,000)
Total net assets acquired						830,000
European Viral Vector Business | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:						302,000
European Viral Vector Business | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:						25,000
European Viral Vector Business | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:						$ 0
Mesa Biotech
Purchase Price
Cash paid					$ 421,000
Fair value of contingent consideration					65,000
Cash acquired					(14,000)
Total purchase price					472,000
Net Assets Acquired [Abstract]
Current assets					54,000
Property, plant and equipment					2,000
Goodwill					237,000
Other assets					3,000
Contract liabilities					0
Deferred tax assets (liabilities)					(72,000)
Finance lease liabilities					0
Debt assumed					0
Other liabilities assumed					(33,000)
Total net assets acquired					472,000
Mesa Biotech | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:					0
Mesa Biotech | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:					279,000
Mesa Biotech | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:					$ 2,000
Lengnau biologics manufacturing facility
Purchase Price
Cash paid				$ 17,000
Fair value of contingent consideration				1,000
Cash acquired				0
Total purchase price				18,000
Net Assets Acquired [Abstract]
Current assets				0
Property, plant and equipment				93,000
Goodwill				18,000
Other assets				364,000
Contract liabilities				0
Deferred tax assets (liabilities)				0
Finance lease liabilities				(82,000)
Debt assumed				0
Other liabilities assumed				(375,000)
Total net assets acquired				18,000
Lengnau biologics manufacturing facility | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:				0
Lengnau biologics manufacturing facility | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:				0
Lengnau biologics manufacturing facility | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:				$ 0
Other
Purchase Price
Cash paid								298,000
Fair value of contingent consideration								117,000
Cash acquired								(12,000)
Total purchase price								403,000
Net Assets Acquired [Abstract]
Current assets								12,000
Property, plant and equipment								2,000
Goodwill								198,000
Other assets								2,000
Contract liabilities								(1,000)
Deferred tax assets (liabilities)								(27,000)
Finance lease liabilities								0
Debt assumed								0
Other liabilities assumed								(11,000)
Total net assets acquired								403,000
Other | Customer relationships
Net Assets Acquired [Abstract]
Definite-lived intangible assets:								2,000
Other | Product technology
Net Assets Acquired [Abstract]
Definite-lived intangible assets:								224,000
Other | Tradenames
Net Assets Acquired [Abstract]
Definite-lived intangible assets:								$ 2,000